|drug2406||Peripheral Blood Wiki||0.71|
|D045169||Severe Acute Respiratory Syndrome NIH||0.03|
|D018352||Coronavirus Infections NIH||0.02|
There are 2 clinical trials
The study researchers think that a medication called N-acetylcysteine can help fight the COVID-19 virus by boosting a type of cell in your immune system that attacks infections. By helping your immune system fight the virus, the researchers think that the infection will get better, which could allow the patient to be moved out of the critical care unit or go off a ventilator, or prevent them from moving into a critical care unit or going on a ventilator. The US Food and Drug Administration (FDA) has approved N-acetylcysteine to treat the liver side effects resulting from an overdose of the anti-inflammatory medication Tylenol® (acetaminophen). N-acetylcysteine is also used to loosen the thick mucus in the lungs of people with cystic fibrosis or chronic obstructive pulmonary disease (COPD). This study is the first to test N-acetylcysteine in people with severe COVID-19 infections.
The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease
Description: Decrease in dyspnea measured by respiratory rate (RR)Measure: Decrease in Respiratory Rate Time: First hour after first dose of NAC
Description: Hospital LOS for admitted patientsMeasure: Hospital length of stay (LOS) Time: Through study completion, average 9 months
Description: Whether a patient needed mechanical ventilation (intubation)Measure: Need for mechanical ventilation Time: Through study completion, average 9 months
Description: If intubated, how long needing mechanical ventilationMeasure: Length of time intubated Time: Through study completion, average 9 months
Description: Outpatients on NAC needing admission to the hospitalMeasure: Need for hospitalization Time: Through study completion, average 9 months
Description: Whether outpatients continued to recover as outpatients; whether admitted patients were managed on medical floors or level of care increased to ICU level of care; whether patients expiredMeasure: Recovery disposition Time: Through study completion, average 9 months
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports